Ranbaxy Seller To Pump Funds Into India’s Fortis, Religare
This article was originally published in PharmAsia News
Executive Summary
The seller of Ranbaxy Laboratories plans to use some of the proceeds from Japan's Daiichi Sankyo to make India's Religare and Fortis health care companies industry leaders in India. Ranbaxy CEO Malvinder Singh said that for the next several years, Ranbaxy would focus on becoming the No. 1 health care company in the country. In the long run, he said, the plan is to phase in Fortis as an international company. He rejected speculation Fortis would be combined with the Anil Ambani group. (Click here for more
You may also be interested in...
Bharat Biotech To Make GSK’s Malaria Vaccine For WHO
GSK is transferring technology to make its malaria vaccine antigen to Bharat Biotech and by 2029 will also transfer rights to supply the vaccine to WHO-approved immunization programs. The deal is expected to improve access via lower cost of the vaccine for such programs
Irish Ad Code Covers OTC Devices And Herbals For First Time
Rules covering OTC medical devices, herbals and online activities have been added for the first time to the Irish Pharmaceutical Healthcare Association's Self-Care Advertising Code.
2020 In Review: HBW Insight’s Five Key Takeaways For The European OTC Industry
HBW Insight extracts five key lessons from 2020, the year the coronavirus pandemic swept its way across Europe.
Need a specific report? 1000+ reports available
Buy Reports